Redeye leaves a comment following Lipum’s announcement that it has been selected, pending final negotiations, to lead a European consortium awarded an EUR8m grant from the Horizon Europe programme. If finalized, the grant would provide meaningful non-dilutive funding to support the company’s upcoming phase II proof-of-concept study with SOL-116 in rheumatoid arthritis.
LÄS MER
